Last reviewed · How we verify

CSII followed by MET — Competitive Intelligence Brief

CSII followed by MET (CSII followed by MET) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin + Biguanide combination regimen. Area: Endocrinology / Diabetes.

marketed Insulin + Biguanide combination regimen Insulin receptor (insulin); AMP-activated protein kinase pathway (metformin) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CSII followed by MET (CSII followed by MET) — Sun Yat-sen University. CSII (continuous subcutaneous insulin infusion) followed by metformin sequentially delivers insulin and then enhances insulin sensitivity to manage blood glucose in diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CSII followed by MET TARGET CSII followed by MET Sun Yat-sen University marketed Insulin + Biguanide combination regimen Insulin receptor (insulin); AMP-activated protein kinase pathway (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin + Biguanide combination regimen class)

  1. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSII followed by MET — Competitive Intelligence Brief. https://druglandscape.com/ci/csii-followed-by-met. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: